Nanomedicine Market Competitive Research And Precise Outlook 2020 To 2026 – Cole of Duty

The global Nanomedicine market report is a comprehensive research that focuses on the overall consumption structure, Demand, Revenue and Forecast till 2026. The report focuses on key companies in the global Nanomedicine industry, market segments, competition, and the growth drivers, constraints and SWOT analysis. This report focuses on Nanomedicine volume and value at the global level, regional level and company level.

(Get up to 20% discount on this)

Request for sample:

https://www.marketinsightsreports.com/reports/07212156415/global-nanomedicine-market-size-status-and-forecast-2020-2026/inquiry?Mode=52

Nanomedicine Market will research at CAGR of 13.5% during the Forecast Period 2017 to 2025.

The Report includestop leading companies Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences

Global Nanomedicine Market, By Type

Quantum dots

Nanoparticles

Nanoshells

Nanotubes

Nanodevices

Global Nanomedicine Market, By Application

oncology

Infectious diseases

Cardiology

Orthopedics

Others

Key Market Trends

Neurological Diseases is Expected to Show Better Growth in the Forecast Period

A large number of brain disorders with neurological and psychological conditions result in short-term and long-term disabilities. The Parkinsons Foundation Prevalence Project estimates that 930,000 people in the United States will be living with Parkinson Disease (PD) by the year 2020. This number is predicted to rise to 1.2 million by 2030. Therefore recent years has observed a significant number of research studies being published on methods for the synthesis of nanoparticle-encapsulated drugs within in vivo and in vitro studies. The insufficient absorbance of oral drugs administered for a range of neurological conditions, such as Alzheimers disease, Parkinson disease, tumor, neuro-AIDS, among others,

North America is Expected to Hold the Largest Share of the Market

In the United States, several companies are closely observing the developments in nanostructured materials across various applications in the healthcare industry, including medical devices, to improve efficiency and efficacy.

For instance, nano-manufacturing in Small Business Innovation Research (SBIR) programs was developed for both commercial and public use. Companies are targeting the treatment of several cancer types and infectious diseases through immunotherapy, where nanoemulsion vaccines and drugs play a significant role. In the United States, one of the major challenges associated with nanotechnology is the ability to integrate nanoscale materials into new devices and systems, along with an application of novel properties at the nano-level. Furthermore, most of the companies are investing in R&D. Nanotechnology is thus likely to play a significant role in the delivery of drugs, which is expected to further advance the research and development activities, over the forecast period.

Global Nanomedicine Market Segmentation by Region:

North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America

Table of Contents:

Report Overview:It includes Nanomedicine market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Nanomedicine market trends and shares market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Nanomedicine market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Nanomedicine market report is studied on the basis of the market size by application, the market size by product, key players, and market forecast.

Key Players:This part of the Nanomedicine market report discusses expansion plans of companies, key mergers and acquisitions, funding and investment analysis, company establishment dates, revenues of manufacturers, and their areas served and manufacturing bases.

Browse This Report:

https://www.marketinsightsreports.com/reports/07212156415/global-nanomedicine-market-size-status-and-forecast-2020-2026?Mode=52

Customization of the Report

The report could be customized according to the clients specific research requirements. No additional cost will be required to pay for limited additional research.

Marketinsightsreports are inspired to help our clients grow by providing business insight with our huge market intelligence repository.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234

Mob: +91-750-707-8687

[emailprotected]

[emailprotected]

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team

The rest is here:

Nanomedicine Market Competitive Research And Precise Outlook 2020 To 2026 - Cole of Duty

Global Nanotechnology in Medical Market is Expected to Grow at Moderate Pace by 2027 Post COVID 19 Pandemic, Latest Market Research Report by…

Nanotechnology in Medical Market report involves all together a different chapter on COVID 19 Impact. The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.Download The report Copy form the webstie: https://cognitivemarketresearch.com/medical-devicesconsumables/nanotechnology-in-medical-market-report

The major players profiled in this report include: Amgen, Merck, Novartis, Roche, Pfizer, Smith and Nephew

Market segment by type can be split into: Nano Medicine, Nano Diagnosis, Other

Market segment by the application can be split into: Hospitals, Clinics, Others

DOWNLOAD FREE SAMPLE REPORT@: https://cognitivemarketresearch.com/medical-devicesconsumables/nanotechnology-in-medical-market-report#download_report

As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall Nanotechnology in Medical globally. This report on Nanotechnology in Medical provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcases market trends and forecast to 2027, factoring the impact of COVID-19 situation.

Nanotechnology in Medical Market report provide an in-depth understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, and opportunities in the market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of last three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garner Nanotechnology in Medical Market revenue by understanding the strategic growth approaches.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Nanotechnology in Medical Market Report 2020 (Coronavirus Impact Analysis on Nanotechnology in Medical Market)

Report provides industry analysis, important insights, and a competitive and useful advantage to the pursuers. The report analyzes different segments and offers the current and future prospects of each segment. Furthermore, this research report contains an in depth analysis of the top players with data such as product specification, company profiles and product picture, sales area, and base of manufacturing in the global Nanotechnology in Medical market. The impact on the supply and demand of the raw materials, due to the COVID-19 is also analyzed in the global Nanotechnology in Medical market.

Additionally, report consists of product life cycle, which discus about the current stage of product. Further, it adds manufacturing cost analysis as well as complete manufacturing process involved. Report also adds supply chain analysis to ensure complete data of market.

Objectives of Nanotechnology in Medical Market Report:To justifiably share in-depth info regarding the decisive elements impacting the increase of industry (growth capacity, chances, drivers and industry specific challenge and risks)To know the Nanotechnology in Medical Market by pinpointing its many sub segmentsTo profile the important players and analyze their growth plansTo endeavor the amount and value of the Nanotechnology in Medical Market sub-markets, depending on key regions (various vital states)To analyze the Global Nanotechnology in Medical Market concerning growth trends, prospects and also their participation in the entire sectorTo inspect and study the Global Nanotechnology in Medical Market size form the company, essential regions/countries, products and applications, background information and also predictions to 2027Primary worldwide Nanotechnology in Medical Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for the next coming yearsTo examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market

Access Exclusive Free Sample Report (COVID-19 Impact Analysis Updated Edition): Click Here>Download Sample Report of Nanotechnology in Medical Market Report 2020 (Pandemic Impact Analysis Updated Edition May 2020)

Follow is the chapters covered in Nanotechnology in Medical Market:Chapter 1 Nanotechnology in Medical Market OverviewChapter 2 COVID 19 ImpactChapter 3 Nanotechnology in Medical Segment by Types (Product Uncategorized)Chapter 4 Global Nanotechnology in Medical Segment by ApplicationChapter 5 Global Nanotechnology in Medical Market by Regions (2015-2027)Chapter 6 Global Nanotechnology in Medical Market Competition by ManufacturersChapter 7 Company (Top Players) Profiles and Key DataChapter 8 Global Nanotechnology in Medical Revenue by Regions (2015-2020)Chapter 9 Global Nanotechnology in Medical Revenue by TypesChapter 10 Global Nanotechnology in Medical Market Analysis by ApplicationChapter 11 North America Nanotechnology in Medical Market Development Status and OutlookChapter 12 Europe Nanotechnology in Medical Market Development Status and OutlookChapter 13 Asia Pacific Nanotechnology in Medical Market Development Status and OutlookChapter 14 South America Nanotechnology in Medical Market Development Status and OutlookChapter 15 Middle East & Africa Nanotechnology in Medical Market Development Status and OutlookChapter 16 Nanotechnology in Medical Manufacturing Cost AnalysisChapter 17 Marketing Strategy Analysis, Distributors/ TradersChapter 18 Global Nanotechnology in Medical Market Forecast (2020-2027)Chapter 19 Research Findings and ConclusionGet detailed TOC for Nanotechnology in Medical Market Report @ https://cognitivemarketresearch.com/medical-devicesconsumables/nanotechnology-in-medical-market-report#table_of_contents.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team, who will ensure that you get a report that suits your needs. You can also get in touch with our executives on to share your research requirements.nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/medical-devicesconsumables/nanotechnology-in-medical-market-report

Read the original here:

Global Nanotechnology in Medical Market is Expected to Grow at Moderate Pace by 2027 Post COVID 19 Pandemic, Latest Market Research Report by...

Small AI biotech BioXcel surges on positive PhIII results, setting up dementia and Alzheimer’s test – Endpoints News

A small biotech added a few hundred million dollars in market value Monday morning after announcing positive Phase III results from their lead neurology drug.

The drug, known as BXCL501, comes from BioXcel, one of a slate of biotechs that has raised millions in recent years on the promise of using artificial intelligence and other advanced computational techniques to speed up the sluggish pace of drug development. Similar to the more prominent Recursion, the company aimed to use its tech to find compounds that other companies or researchers had validated to some degree and repurpose them, particularly in the areas of neurodegeneration, mental health and immuno-oncology.

Now, in a pair of nearly 400-person Phase III trials for bipolar disorder and schizophrenia, the lead drug effectively calmed patients agitation, as measured by a standard scoring system. It also hit secondary endpoints, showing the effect began as early as 20 minutes after dosing.

The company said it plans to submit for approval in the first quarter of 2021. Their stock soared 31%, from $52.99 to $69.40 pre-market on the news.

In our view, these data are very compelling, Guggenheim Partners Yatin Suneja wrote in a note to investors, and we expect approval in both indications.

Suneja said the results looked in-line or better than Adasuve, the Alexza drug used as the standard of care for agitation. She predicted $500 million in peak sales.

When BioXcel filed for its IPO in 2017, though, the company spent as much time talking about its lead drugs potential in Alzheimers and dementia as it did about schizophrenia. Although further behind, that indication so sought out by biotech in recent years remains the companys largest market potential. A Phase I/II trial is now underway.

The larger focus for investors is dementia, larger market than schizophrenia/bipolar, SunTrusts Robyn Karnauskas wrote in a note to investors.

She said the Phase III numbers supported $800 million in peak sales, while pointing to even greater potential in neurodegeneration. We believe data helps validate targeting a central mechanism related to acute agitation and as such, should help expand BXCL501 into additional indications, she said.

That mechanism involves a reformulation of Pifzers 21-year-old sedation drug Precedex. BioXcel created a sublingual version of the drug that can be given easily and produce a calming effect without knocking a patient out. Specifically, it activated the alpha-2 receptor, the pathway through which norepinephrine, among other neuro-chemicals, travels.

In the Phase III studies, the drug reduced patients excitement score on the Positive and Negative Syndrome Scale for schizophrenia and bipolar disorder. Across 381 schizophrenia patients, those on the high dose had 10.3 point reduction after 2 hours, compared with 8.5 on the low dose and 4.8 on placebo. Across 378 bipolar patients, the high dose arm and 10.4 point reduction, compared with 9.1 on the low dose and 5 on placebo.

Patients also showed statistically significant improvements on the Agitation and Calmness Evaluation Scale (ACES), and clinical global impression.

Social image: Vimal Mehta, BioXcel CEO

Continue reading here:

Small AI biotech BioXcel surges on positive PhIII results, setting up dementia and Alzheimer's test - Endpoints News

3 systems to threaten US, Caribbean with tropical rain and wind – KPQ

There are three systems from the Atlantic to the Pacific Ocean that could threaten the U.S. and Caribbean with tropical rain and wind.

The most imminent storm is tropical depression eight, which is forecast to become Tropical Storm Hanna. It is forecast to bring heavy rain and flash flooding to Texas.

Because this storm is expected to become Tropical Storm Hanna in the next 24 hours, a tropical storm watch has been issued from Houston to Corpus Christi, Texas, and down to near the Mexican coast.

The system will be slow moving, so flash flooding will be the biggest threat in Texas and the western Gulf Coast. However, this weak tropical cyclone is not expected to be particularly strong and winds wont be the biggest threat.

More than 6 inches of rain is possible in some areas.

Tropical Storm Gonzalo is currently packing winds at 65 mph as it heads east toward the eastern Caribbean islands.

It is expected to become a hurricane later Thursday and continue strengthening as it nears Grenada, Barbados and Trinidad and Tobago by Saturday afternoon.

Hurricane force winds will reach near 80 mph with higher gusts possible. Flash flooding will be the biggest threat on these eastern Caribbean islands this weekend.

After that, it is still uncertain where Gonzalo will go from there and how strong it will be, but the latest path takes it south of Puerto Rico and the Dominican Republic Sunday night into Monday morning.

Meanwhile, Hurricane Douglas, a major Category 3 storm, is packing winds of 120 mph.

This is the first major hurricane of the season in the eastern Pacific.

It is expected to strengthen somewhat in the next 24 hours and then weaken as it heads for Hawaii.

The current Hurricane Douglas track takes the storms path toward Hawaii by Saturday night.

The biggest threat in Hawaii will be flash flooding and mudslides this weekend.

Read the original:

3 systems to threaten US, Caribbean with tropical rain and wind - KPQ

Rum Journal: Rude Bwoy and the Spirit of the Caribbean – Caribbean Journal

The newest rum brand to hit the market is Rude Bwoy, a collection of rums born out of a deep family connection to the Caribbean.

The brand is the brainchild of Patrick Mitchell and James Larson, who have cultivated both white, gold and flavored rums (along with a vodka, too), celebrating Mitchells familys centuries-long roots in both Jamaica and Cuba.

To learn more, Caribbean Journal talked to Mitchell and Larson about Rude Bwoy and whats next for the company.

Patrick, can you talk about your familys connection to the Caribbean?

Our story begins on the Caribbean island of Jamaica, in the West Indies, back in the 1600s with the Wright family. The Wrights were living on the south side of the island in the parish of St. Elizabeth in a town named after the family. At the time, Wright Town stretched from the hills of Spur Tree to the beaches of Treasure Beach and Newell. The Wrights were serial entrepreneurs selling cattle and grew peanuts, onions, melons and scallion and of course sugar.

Our more recent Jamaican family was livestock famers. My grandfather was a cattleman and sold crops from his property as one of the best salesmen in the area. It was here that the ideas to start producing rum formed.

The Wrights were humble people who worked the sugar and cattle for their family. When opportunities for better pay came to Jamaicans by the building of Cubas railroads, some of the elder Wrights headed off to Cuba taking the opportunity.

The Wrights that went to Cuba tried hard to stay in connection with their Jamaican family, however back then communication was very thin.

Over time, the family spread out, some going to other countries such as England, and Costa Rica and to America. It wasnt for over a century later that Cubas revolution was the forefront of the world bringing rum right along with it.

What is a Rude Bwoy?

Rude Bwoy, sometimes also called Rudie is an endearing term for ones bredrin, friend, mate, and also sometimes used to identify a youth or child that is a cool yute. The term was born after the emergence of the Ska Music scene when Reggae music was on its way in Jamaica.

RudeBwoyhas four spirits. What are they?

All our spirits are 100% natural.

Ultra Premium Rude Bwoy Vodka

Ultra Premium Rude Bwoy Irie Gold Rum

Ultra Premium Rude Bwoy Irie White Rum

Ultra Premium Rude Bwoy Coconut Rum

Where is the rum made?

Our rum is made at The Point Distillery in the Tampa, FL area

The coconut rum is particularly unique what makes it special?

Our award-winning Ultra Premium Coconut Rum is a real game changer in the marketplace. Unlike most flavored rums on the market, it is made with 100% natural ingredients-nothing artificial. We like to say its literally made from the ground up. At 70 proof, its also stronger than most flavored rums in the market place and its exceptionally smooth with just the right tropical aromatic finish.

Whats the best way to drink Rude Bwoy?

Weve found most people truly enjoy our coconut rum on the rocks with a lime or with just a splash of your favorite mixer. Our mixologist, Bree Draughon, is constantly creating exciting new Rude Bwoy cocktails with our full lineup as we roll out the product across the nation.

Our very unique sugar cane Vodka has also become very popular with the Bloody Mary crowd with its very smooth and exciting twist versus the traditional vodka offerings.

RudeBwoyalso has apparel for sale. Do you foresee Rude Bwoy being a brand beyond the rum?

With our Caribbean-focused brand, as well as both partners background in the surfing, beach volleyball and reggae scenes, our apparel is a unique island inspired lifestyle brand that we intend to leverage along with our spirits.

Rum as a spirit has come a long way. What do you see as the future for rum?

We believe the future is very bright for high quality, ultra premium rum offerings. Consumers are interested in enjoying the content, quality, and the story behind brands. At Rude Bwoy, our story is quite unique and we encourage our customers to Taste the Experience which transcends most cost hurdles. Consumers are also gravitating very robustly to the all natural and organic components of high quality rums which also elevates the future of the rum sector.

For more, visit Rude Bwoy.

Read the original:

Rum Journal: Rude Bwoy and the Spirit of the Caribbean - Caribbean Journal

Medical students launch ‘Leading the Rounds,’ to explore leadership development in medicine podcast – The South End

Peter DimitrionCaleb Sokolowski

Wayne State University School of Medicine students Peter Dimitrion and Caleb Sokolowski have jumped into the popular world of podcasting as the creators and hosts of Leading the Rounds: A Medical Leadership Podcast.

We began this podcast because we are both passionate about leadership development, which is its own field and needs to be studied like pathology, biology and more, said Dimitrion, a second-year M.D./Ph.D. student. There are few resources for medical trainees that are accessible and affordable. Leadership development is overlooked in contemporary medical education, yet medical students and physicians find themselves in leadership roles from the beginning of their training. Other industries, such as the military and business, have formal leadership development courses, but physicians receive no formal leadership training as a part of their medical curriculum. We want to meet this need and improve our comprehension and understanding of leadership principles.

His co-host is also in his second year of the M.D. program. Dimitrion and Sokolowski published seven episodes so far, with guests including Army Maj. Cal Walters and Paul Thomas, M.D., a Class of 2013 alumnus and founder of the direct primary care clinic Plum Health in Detroit.

The show will focus on three facets they believe are critical to their development as future medical leaders: leadership development, personal development and health systems literacy.

Leading the Rounds is available on Apple Podcasts or Spotify.

We also have a website,www.leadingtherounds.com, which we are constantly updating with links to our episodes and resources for anyone who isinterestedin following up on the ideas that we talk about in our podcast. People can also connect with us on Instagram @Leadingtherounds, Dimitrion added.

Read this article:

Medical students launch 'Leading the Rounds,' to explore leadership development in medicine podcast - The South End

Neely offers Northwest Missouri medicine in governor run – News-Press Now

NORTH KANSAS CITY, Mo. Jim Neely is running a tight-knit, community focused campaign; for the Cameron, Missouri, physician and decades-experienced public servant, there isnt any other way to do it.

Hes pursuing a run for governor, the first from rural Northwest Missouri to seek the states top job in some time, with a message designed to advance conservative principles while hoping to leverage popular frustrations with what he labels typical Jefferson City politics. He took a moment at a campaign meet-and-greet event on Thursday to elaborate on this.

Weve got challenges and, you know what, the citizens see this, he said. Theres a relationship problem between taxpayers and government.

Mike Larkin of Plattsburg, Missouri, a retired airline pilot for TWA, attended the Neely event on Thursday at Repeal the 18th Bar and Bistro in North Kansas City, Missouri, after following Neelys career in public service for some time. Larkin said it is one of his most important values that the Show Me State be run by working professionals from rural America, preferably Northwest Missouri.

It means everything, Larkin said. Everything. I have watched what goes on in Jeff City for 40 years, and none of us can be very happy with our state government. Bad politics seem to permeate, no matter what side youre on.

Beyond his service in the state legislature since his first election in 2012, Neely still practices medicine, serving assisted living facilities in local communities in association with the Cameron Regional Medical Center; hes practiced medicine there since 1987.

He originally hails from Tarkio, Missouri, and moved at a young age to Forest City, Missouri. In his young adult life, Neely served in the U.S. Army as an infantry officer from 1974 to 1976, separating with the grade of first lieutenant. Neely was on the Cameron R-I school board from 1996 to 2005.

So, my ties to Northwest Missouri are significant, he said. I love Northwest Missouri.

Theres no way to run a Republican campaign for governor these days without acknowledging the elephant in the room of COVID-19, and Neely is in a particular position to do that as a practicing medical doctor. He described himself as a skeptic of mandatory requirements for masks, of the like that apply in Jackson County where the Thursday event took place.

At the end of the day, Neely believes that rural leaders should push back on broad mandates. Those who feel compelled to wear masks to protect themselves and others should do so, he said, but this is not the governments role to enforce.

We need to be all going right back, back to the normal we had in January and February, back to work, he said. People will be happier and healthier.

Read more from the original source:

Neely offers Northwest Missouri medicine in governor run - News-Press Now

To begin addressing racial bias in medicine, start with the skin – STAT – STAT

Until the color of a mans skin is of no more significance than the color of his eyes. Bob Marley, War

Racial inequity in the U.S. health system is, in many ways, far deadlier than police violence.

The failures of the health care industry to appropriately care for Black patients are well-documented, resulting in the lowest life expectancy of any major group in the U.S. In addition to poverty, lack of access to care, and inadequate treatment, people of color are also dying due to bias in medical education, clinicians insufficient exam skills, and lack of appropriate information tools. The medical community needs to wake up and start fixing the way we recruit, train, and equip clinicians to reverse the trend of Black Americans dying too early and too often.

advertisement

My specialty, dermatology, is a prime example of the kinds of changes we need.

The skin is considered a window into health. But clinicians who havent been properly trained often fail to see some conditions in patients with Black skin. Reggae pioneer Bob Marley died of melanoma, a treatable skin cancer that is often missed and misdiagnosed in Black people. It becomes fatal if left untreated.

advertisement

Ive seen patients of color misdiagnosed because clinicians could not recognize their rashes. Ive seen immunologic diseases such as lupus, life-threatening drug reactions, and other conditions that manifest themselves on the skin get missed for the same reasons. I recall one very ill patient who was transferred to our hospital two weeks after a life-threatening drug reaction began from a sulfa-based antibiotic used to treat a urinary tract infection. She had body-wide blistering and ended up in the burn unit because the nurse and physician who initially evaluated her did not recognize the early skin clues and missed the diagnosis entirely. It was a miracle that she survived.

What went wrong in that case is a sadly common occurrence.

Inflammation caused by increased blood flow appears red or pink on white skin. Thats what clinicians are trained to recognize. In brown or Black skin, though, inflammation often appears brown or violaceous. Most medical and nursing students, and even many experienced clinicians, dont know that because most medical textbooks severely underrepresent disease manifestations on pigmented skin. This failure to train clinicians to effectively diagnose disease in people with pigmented skin contributes to lopsidedly negative outcomes for Black patients.

But unlike many of the pervasive economic, historic, and cultural factors driving poor health in the Black community, we can fix this problem today by having health systems and medical and nursing schools teach the skin exam in people of color to reduce error and bias; train clinicians about specific treatments for diseases that occur more often in patients of color; and advance tools and education that position clinicians to provide excellent care for every patient.

Racial bias in medicine is also tied to the images clinicians use to communicate with their patients. Showing patients one or more pictures of their condition is highly effective for communicating a diagnosis, educating them, and building trust. This is especially true in the current environment of Covid-19 when telemedicine is increasingly being used. But when people of color have their clinicians explain a disease process with images that do not look like them or their condition, it creates confusion, undermines trust, and ultimately affects patient behavior and outcomes.

Early on in my career, I recognized that showing reference images to patients that represent not only their condition but also their skin type can transform the conversation. It takes less than a minute to show a patient a comparable image to explain his or her diagnosis, but it makes a monumental difference and it shows you took the time to care.

Practices, clinics, and hospitals need to diversify their patient education materials to start dissolving these barriers to better patient-doctor relationships and optimal patient health. Medical image databases, books, and decision support tools must showcase the entire spectrum of skin colors to better represent the diverse patient populations we care for. By teaching clinicians-to-be using a range of skin types, and increasing access to diverse images that build patient knowledge and trust, we can start bringing equity to the practice of medicine, diagnosis, and patient education.

The horrific death of George Floyd has led many white Americans like me to reexamine our personal biases and the structural racism that has plagued our country since its founding. Medical professionals must address racial disparities in care immediately and start taking the life-expectancy gap for Black Americans as seriously as any other factor contributing to the deaths of thousands of people every year. To do this, we all need to acknowledge that racism in medicine is not simply about poor access, inequitable care, or hiring bias it is also at the core of how we teach and practice medicine with people of color. We can, and must, do better.

Art Papier is a physician and CEO of VisualDx, a medical informatics company affiliated with the University of Rochester.

Read the rest here:

To begin addressing racial bias in medicine, start with the skin - STAT - STAT

RNA, Data Science, and the Future of Precision Medicine – Clinical OMICs News

Jarret Glasscock, CEO of Cofactor Genomics, recently spoke with Patrick Hurban, Senior Director and Global Head, Translational Genomics at Q2 Solutions on the topic of onboarding novel technologies for clinical studies. Dr. Hurban leads a team of laboratory-based and bioinformatics scientists who evaluate, develop, validate, and implement all of the genomic capabilities offered throughout the Q2 global laboratory locations. Dr. Hurban also serves as Laboratory Director for their CAP/CLIA Genomics Center of Excellence laboratory in the Research Triangle Park, North Carolina.

Jarret: How do you see novel technologies making an impact in precision medicine?

Pat: Precision medicine is critically reliant on biomarkers. While contemporary technologies have done a good job of identifying potential biomarkers and translating them to diagnostics, its sobering to realize that as of today in the U.S. there are only 38 approved companion diagnostics, and that doesnt represent 38 distinct targets, many of those are overlapping. The field often thinks of the therapeutic first, with the companion diagnostic then added on. But the paradigm is shifting. Personally, Im really excited by diagnostics that can be tied to multiple therapieswhat some have termed a companion therapeutics strategy. Genomics is particularly relevant in this framework, and weve already seen approvals of NGS-based tests covering multiple therapeutics and multiple indications, as well as tissue-agnostic markers like microsatellite instability-high. I look forward to technology advances that enable cost-effective and rapid integrative multi-omic testing.

Jarret: How does your team onboard new technologies into your laboratory?

Pat: We use a phased approach. We strongly prefer forging technology partnerships, as opposed to simply purchasing things through a customer/vendor relationship. Our technology portfolio must remain current and relevant to our clinical development clients, so we take every client interaction as an opportunity to understand their evolving needs and identify ways of working together to identify and evaluate potentially interesting technologies. Our clients rely on our objectivity, so we conduct evaluations that are designed to pressure-test the claimed capabilities of a technology, but also to determine whether its feasible to deploy the technology as part of clinical trialswe must always be mindful that no matter how interesting a technology is, if we cant collect, store, transport, and process the sample within stability, its not a workable solution for trials. And solutions that work in trials conducted in an academic medical center setting may not work in a community care setting. Once weve identified something of interest, our implementation will include a validation commensurate with the intended use of the technology, and we will work closely with our colleagues in our production laboratory to engineer an operationalized, scalable, and sustainable workflow.

Jarret: Why is immune profiling important to your clients and partners?

Pat: Immuno-oncology approaches have revolutionized cancer research and treatment. Despite the tremendous advances we have made to date, no one would deny that we have only scratched the surface of the vast complexity of the immune response to tumors. Clearly, new therapeutic avenues and biomarker possibilities are opened with each incremental advance of our understanding. In clinical development theres always a tension between having a narrow focus that enables strong, definitive findings, and casting a wider net using broader profiling solutions. We have need of both, since so many trials seek to confirm biomarker hypotheses as well as generate new hypotheses.

Jarret: When do you believe well see the next generation of technologies transition into clinical practice?

Pat: Sooner than any of us are ready for. So many of the newer technologies are showing such promise, with the possibility of illuminating our understanding of tumor biology in fundamentally new ways, so there is a huge push from our clinical development partners to find ways to incorporate nascent technologies. All of this is aimed at ultimately finding biomarkers that can be translated into routine use.

Jarret: What differentiates Q2 Solutions from other CROs?

Pat: Leading with science. We have the most effective combination of operational excellence and scientific acumen available today. We offer outstanding science and a breadth and depth of technical knowledge that is unrivaled in the industry. We take the long view and have a track record of investing in people and technology to propel clinical trials forward. We engage early and understand that the success of our partners is the best measure of our own success..

The rest is here:

RNA, Data Science, and the Future of Precision Medicine - Clinical OMICs News

Preventing injuries and treatment for women with Avera Orthopedics and Sports Medicine – KELOLAND.com

If you're a lover of prairie music--and who isn't? We do live in the prairie afterall--then you are going to love this weekend's Levitt in Your Living Room guest. Levitt at the Falls Executive Director, Nancy Halverson, joined us in the studio to tell us more about the upcoming Levitt in your Living Room virtual concert on July 25th. And we were also being joined by the next Levitt in Your Living Room musical guest, Carrie Newcomer, who joined us through Zoom. They joined us to tell us what we can expect when we tune into this weekend's virtual event.

This weekend's Levitt in your Living room guest lives in the woods of Southern Indiana with her husband and two shaggy dogs. Yet, it only takes one listen to her music to know that Carrie Newcomer has a deep love for this country and it's rich heritage. Take a listen for yourself.

Read more from the original source:

Preventing injuries and treatment for women with Avera Orthopedics and Sports Medicine - KELOLAND.com

UNLV Medicine allows patients with COVID-19 to attend some in-person appointments – ABC17News.com

Click here for updates on this story

LAS VEGAS, NV (KVVU) UNLV Medicine allows patients with confirmed cases of COVID-19 to attend some in-person medical appointments, officials confirmed to FOX5 on Wednesday.

A staff member who spoke to FOX5 said that they previously scheduled patients with COVID-19 for telehealth appointments only. The staff member, who requested anonymity in speaking to FOX5, said the organizations scheduling department informed staff that they could now schedule people who have tested positive for COVID-19 for in-person medical appointments.

In a statement provided to FOX5, UNLV Medicine confirmed that they will see patients who have knowingly tested positive for COVID-19 if the patient is not sick enough for the ER, but for whom its important to be seen by their doctor for appointments such as high risk pregnancies, etc.

UNLV Medicine provided the below statement:

We strongly advise patients who are COVID-19 positive to isolate themselves and manage their illness at home. If they need to speak to, or be seen by a doctor, we offer telehealth appointments.

Only if they are very sick do we recommend a patient go to the ER, as it is important during the pandemic not to overcrowd hospital emergency departments with those not requiring emergent care.

For patients not sick enough for the ER, but for whom its important to be seen by their doctor for appointments such as high risk pregnancies, etc, during those rare occasions we will see them, as it would be irresponsible for us as healthcare providers not to.

All our patients should feel confident that as frontline healthcare providers we have world- class safety protocols in place to protect all patients and employees during this pandemic. Those same protocols have been successfully used to keep our patients, doctors and medical assistants safe while conducting COVID-19 tests on more than 17,000 Nevadans since March 23rd.

UNLV Medicine

Please note: This content carries a strict local market embargo. If you share the same market as the contributor of this article, you may not use it on any platform.

Read the original here:

UNLV Medicine allows patients with COVID-19 to attend some in-person appointments - ABC17News.com

Why are re-purposed medicines expensive? – The Hindu

The quest for developing a vaccine and finding a definitive treatment for COVID-19 treatment is reportedly making good progress. However, with the number of infections around the globe having crossed 14.7 million, there is no easy containment of this pandemic. Clinical trials with re-purposed antivirals and biologicals have been approved in different geographical settings. These medicines are believed to have some potential in shortening the recovery time in COVID-19 patients. Recently, the Drugs Controller General of India (DCGI) issued approval to Glenmark Pharma to manufacture and market Favipiravir tablets for restricted emergency use. It also issued approvals to Hetero and Cipla to manufacture and market injectable formulations of Remdesivir, and to Biocon Limited to market injectable formulations of Itolizumab.

Also read: Glenmark Pharma cuts price of COVID-19 drug by 27% to 75/tablet

Remdesivir is an antiviral originally developed by Gilead to treat the Ebola virus infection. Favipiravir is a generic version of an anti-influenza medicine developed by Toyama Chemical in Japan. Gilead has entered into royalty-free voluntary licensing agreement with companies including Hetero and Cipla to provide technology transfer to manufacture Remdesivir for distribution in 127 countries. The free royalty period is valid until the World Health Organization (WHO) declares the end of the pandemic or until another medicine or vaccine is approved to treat or prevent COVID-19. Hetero has priced Remdesivir at 5,400 for a 100 mg injection vial, and Cipla at 4,000 per vial. A five-day treatment course with Remdesivir would work out to 24,000-32,000 per patient. Glenmark claims to have developed the active pharmaceutical ingredient and formulation of Favipiravir through its in-house research team and has priced Favipiravir 200 mg tablet at 103, with a course of treatment costing 12,566 per patient. Both these medicines inhibit viral RNA-dependent RNA polymerase, thereby retarding viral replication in host cells. Itolizumab, incidentally used in the treatment of psoriasis, reportedly shows therapeutic effects in severe COVID-19 infections progressing to acute respiratory distress syndrome. Treatment with Itolizumab is also not inexpensive by any means with the medical costs amounting to 32,000 per patient. The critical question is whether the above pricing would exclude a majority of the patients from the benefits of these re-purposed medicines.

The updated clinical management protocol of the Ministry of Health and Family Welfare (MHFW) lists Remdesivir as a potential medicine for investigational therapy in moderate COVID-19 infections without underlying contra-indications. The protocol does not mention Favipiravir, which nevertheless finds a place in the WHO Clinical Management Protocol. Itolizumab figures neither in the MHFW nor in the WHO protocol.

The question that begs an answer from pharmaceutical companies marketing re-purposed medicines for restricted emergency use is whether these medicines can be made available at affordable prices to patients. The current pricing does not indicate this. Andrew Hill et al in their study published in the Journal of Virus Eradication determined the price of final finished product (FFP) or medicine ready for use, by adding the costs of the active pharmaceutical ingredient, excipients, formulation, packaging and a reasonable profit margin. Their calculations have estimated the cost for a treatment course with Remdesivir to be $9 and the estimated production cost for a course with Favipiravir to be $20 per patient. Itolizumab has not been subjected to a costing analysis in their study.

Affordability of medicines is a matter of particular concern. When companies attempt to recover the fixed costs or sunk costs that went into the investment and development of the medicine, the final price becomes unreasonable. This is distressing for the patient, especially when the therapeutic results or clinical benefits have not been fully established.

Akin to the flexibilities in the TRIPS agreement which helped in making antiretrovirals affordable during the AIDS crisis, some countries are resorting to enabling legislation and procedural modifications of existing regulations to address affordability of anti-COVID-19 medicines. Israel issued a compulsory licence to Hetero for production and import of the Lopinavir-Ritonavir combination from India, following which the innovator AbbVie decided not to enforce its patent right. Canada passed the COVID-19 Emergency Response Act and Germany, The Prevention and Control of Infectious Diseases in Humans Act. Chiles Lower House of Parliament and Ecuadors National Assembly passed resolutions allowing TRIPS flexibilities in the pandemic. Prompted by Costa Rica, WHO opened a voluntary patents pool, for compiling and sharing information and technological know-how for the development of medicines, vaccines and diagnostics for COVID-19.

Indian patent laws too are armed with sufficient powers to ensure reasonable pricing for pharmaceutical products. India has used compulsory licensing only once in 2012 for Sorafenib. Section 92 of the Act enables grant of compulsory licensing in circumstances of national emergency or extreme urgency. Compulsory licences may not be the solution in all such situations. Nevertheless, the pricing will have to reflect the magnitude of the crisis and the socioeconomic realities in individual countries.

Many innovator companies, perhaps to escape or avoid any coercive move or legal action by governments, agree upon voluntary licences with generic companies. Such tie-ups can cause substantial reduction of medicine prices, as was seen in the case of Sofosbuvir, the $1,000 anti-hepatitis C medicine. Its price went down to approximately $10 per tablet in India, subsequent to the innovators voluntary licences with Indian generic companies in 2014. The terms and conditions of such agreements are generally wrapped in secrecy and may have clauses detrimental to public interest. Besides, as allegations of cartelisation between innovators and generic companies were raised in the case of antidiabetics Sitagliptin and Vildagliptin in the past, such arrangements are generally viewed with suspicion.

The prices announced for the re-purposed medicines appear to be high, especially given the rate of spread and the public health crisis in India. Economies of scale will ensure that the companies recoup their investment costs, and still generate profits. The burden of a global pandemic will have to be borne by governments and pharmaceutical companies alike. Unprecedented public health crises call for situation-specific decisions from pharmaceutical companies and profit maximisation should take a back seat. At least there is a strong case for reconfiguring the pricing strategies of the re-purposed medicines for COVID-19 treatment.

Sharmila Mary Joseph is Secretary, Department of Ayush, Government of Kerala, and James J. Nedumpara is Professor and Head, Centre for Trade and Investment Law, Indian Institute of Foreign Trade, New Delhi. Views are personal

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Original post:

Why are re-purposed medicines expensive? - The Hindu

SLU, Washington University School of Medicine to host COVID vaccine trials in the coming weeks – KTVI Fox 2 St. Louis

ST. LOUIS The historic effort to find a coronavirus vaccine comes to St. Louis.

Both the St. Louis University (SLU) Center Vaccine Development and the Washington University School of Medicine are looking for thousands of volunteers for Phase 3 efficacy trials for potential vaccines.

This is the last phase before FDA approval.

These are the trials that will tell us whether or not the vaccine actually works or does not work, said Dr. Sharon Frey, clinical director of SLUs Center for Vaccine Development and principal investigator of the trial at SLU.

The trials will involve at least two of five vaccines on the verge of making it this far: through initial vaccine development and the first two phases of smaller group clinical trials.

The Phase 3 efficacy trials will study tens of thousands of people across the country.St. Louis researchers are looking for about 3,000 volunteers from this area who have not already tested positive for COVID-19.

They must be at least 18 but theres no upper age limit. Those over age 65 are encouraged to participate.

Volunteers would not be exposed to COVID-19 as part of the trials, researchers said.Theyd get either an actual dose of vaccine or a placebo.

The studies are not going to expose anybody to the virus, said Dr. Rachel Presti, director of Washington Universitys Infectious Disease Clinical Research Unit. Were just going to see if getting the vaccine protects you from getting infected more than getting a placebo or saline injection. We want to see if it protects people from getting infected. We also want to see if it protects people from getting really, really, sick People are afraid to touch each other and hug each other and do the things they normally do. Really, were thinking might be our best shot to getting past that.

Phase 3 trials are expected to begin in the US next month. Theres still hope for having a safe, effective, vaccine by the end of the year.

This is an opportunity for St. Louis to be in the forefront of making history with these vaccine studies. It is everybodys chance to help make a difference, Dr. Frey said.

For more information about vaccine trials at Saint Louis Universitys Center for Vaccine Development, please visit http://vaccine.slu.edu or call 314-977-6333 or 1-866-410-6333; or email vaccine@slu.edu. Contact Washington University School of Medicine at 314-454-0058 or by email at Idcru@wustl.edu.

You can also check http://www.CoronavirusPreventionNetwork.org.

Go here to see the original:

SLU, Washington University School of Medicine to host COVID vaccine trials in the coming weeks - KTVI Fox 2 St. Louis

#ShareTheMedicalMic campaign aims to amplify the voices of Black women in medicine – KGW.com

On Wednesday, 40 physicians, including a Portland OBGYN, will hand over their social media accounts to 40 Black female physicians.

PORTLAND, Ore A Portland doctor is lending her social media presence to an effort that highlights the voices of Black women in medicine.

This week OBGYN Dr. Jennifer Lincoln will turn over her Twitter and TikTok accounts as part of a national campaign called #ShareTheMedicalMic.

"Maybe that seems silly and you might say, 'Well, its just social media,'" Dr. Jennifer Lincoln said. "Well, your thoughts are what you see. So, make your feed what this world looks like which is not just people who look like you and people who believe the same things as you but diversify it and learn from that."

In June, celebrities started a new initiative on social media called #ShareTheMicNow to amplify Black voices in Hollywood, handing their accounts over to them for a day. Now, two physicians are bringing that effort to their field.

Dr. Renee Paro and Dr. Lauren Powell created the campaign for Black voices in medicine as we still see disproportionate numbers of health conditions and deaths that affect the Black community, according to Dr. Lincoln.

On Wednesday, July 22, Dr. Lincoln will join dozens of colleagues across the country to encourage that conversation and call attention to Black female voices in medicine. 40 female physicians, including Dr. Lincoln, will hand over their social media accounts to 40 Black female physicians.

"These women we are featuring are amazing," said Dr. Lincoln. "They are leaders in their communities, leaders in their field. A lot of them are mothers and are juggling so many things and I think that they deserve this recognition."

A few years ago, Dr. Lincoln saw the positive impact female physicians could make by connecting with people online. Now, with more than 45,000 Instagram followers and 780,000 followers on TikTok, she uses her social media presence to talk about important issues of women's health and racism.

"In this day and age, we are realizing how siloed we are and if anything in the past two weeks has shown us it's that we need to be listening to all voices. This is not a new narrative, but it's a narrative that we need to bring into the mainstream, and we need to get out there," she said. "And so, we're giving them the mic. We're giving them the accounts and saying, 'Okay, get your voice out there. Say what you need to be heard' so that they can expand their audiences and speak to what they want to."

Only about 5% of doctors in the United States are Black and about 2% are Black women, according to the Association of American Medical Colleges.

"That's just a ridiculous disparity," Dr. Lincoln said.

Dr. Lincoln hopes the #ShareTheMedicalMic initiative will shed light on this disparity and others. She knows the world of social media can be a divisive place but says it can also be a force for good.

"The positives, when it comes to these communities of underrepresented groups [is] the ability to connect and see that you're not alone and amplify that is amazing," she said.

This Wednesday,Dr. Jessica Shepherdwill take over Dr. Lincolns Instagram page.

"When I look at her, I'm like, 'That's what I want to be when I grow up,'" Dr. Lincoln said.

A fellow OBGYN, mom and media personality, Dr. Shepherd and Dr. Lincoln have a lot in common. They hope to soon share a wider audience as well.

"We get to, kind of, expose each other's audiences to both of us because we both have so many similarities, but the differences too are important, and I love that because it makes us unique," said Dr. Lincoln.

Follow #ShareTheMedicalMic all day Wednesday and check out @DrJenniferLincoln on Instagram to see Dr. Shepherd's message.

You can also follow Dr. Shepard on Instagram at @jessicashepherdmd

Dr. Shepherd also plans to hold a live Instagram conversation at 6 p.m. PST Wednesday.

Read the rest here:

#ShareTheMedicalMic campaign aims to amplify the voices of Black women in medicine - KGW.com

Anika To Launch Six FDA-Cleared Sports Medicine and Extremities Products in Third Quarter of 2020 – OrthoSpineNews

BEDFORD, Mass., July 20, 2020 (GLOBE NEWSWIRE) Anika Therapeutics, Inc.(NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced U.S. Food and Drug Administration (FDA) clearance and the planned launch of multiple new product innovations that address the needs of orthopedic and sports medicine surgeons and their patients seeking to stay active by overcoming soft tissue damage. Six minimally invasive surgical devices and instruments have been cleared by the FDA to repair rotator cuffs, perform arthroscopic knee repairs and treat arthritis damage in the hand and wrist. The products will be commercialized through Anikas recently expanded sales and marketing team throughout the third quarter of 2020 and mark the first products launched from the acquisitions of Parcus Medical and Arthrosurface, which were completed earlier this year.

Anika has rapidly pivoted to become a dynamic, customer facing enterprise. The introduction of these innovative technologies is evidence that the Company is listening to its physician customers to identify surgeon and patient needs, and has the ability to develop, gain approvals for and launch a series of new devices and instruments, even during pandemic conditions, said Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika. Commercial success and growth in the sports medicine and joint preservation and restoration market demands an evolving understanding of unmet patient needs and the ability to translate surgeon feedback into designs that are both meaningful and practical for todays minimally invasive surgical ecosystem. Anika is well positioned to launch these exciting innovations, and we look forward to introducing these new products to our growing customer base as COVID restrictions ease and elective procedures resume in the U.S.

The new products include:

Consistent incremental improvements to techniques, tools and materials are critical in joint preservation surgery, allowing surgeons to continually refine ways to keep their patients active and comfortable, said Anil S. Ranawat, M.D., Hospital for Special Surgery. Having worked closely with the Anika team in recent years, I am impressed with their ability to identify clinical problems and provide real time solutions for us as practitioners. Their growing armamentarium of new tools is the most recent example of this commitment, and I look forward to putting them into practice.

About Anika Therapeutics

Anika Therapeutics, Inc.(NASDAQ: ANIK), is a global, integrated joint preservation, restoration and regenerative solutions company based in Bedford, Massachusetts. Anika is committed to delivering a diverse array of products to improve the lives of patients, with a focus on osteoarthritis pain management, sports medicine and joint preservation, restoration and regeneration. The Company has close to three decades of global expertise commercializing innovative products across the orthopedic early intervention continuum of care. For more information about Anika, please visitwww.anikatherapeutics.com.

Forward-Looking Statements

The statements made in the first and third sentence of the first paragraph, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the Companys planned product launches. These statements are based upon the current beliefs and expectations of the Companys management and are subject to significant risks, uncertainties, and other factors, especially in light of the evolving landscape around the COVID-19 pandemic. The Companys actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Companys failure to realize the anticipated benefits of its recently completed acquisitions; (ii) unexpected expenditures or assumed liabilities that may be incurred as a result of these acquisitions; (iii) loss of key employees or customers following the acquisitions or otherwise; (iv) unanticipated difficulties in conforming business practices, including accounting policies, procedures, internal controls, and financial records of the recently acquired companies; (v) inability to accurately forecast the performance of the recently acquired companies resulting in unforeseen adverse effects on the Companys operating results; (vi) synergies between the recently acquired companies and the Company being estimates which may be materially different from actual results; (vii) the Companys ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (viii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (ix) the cost effectiveness and efficiency of the Companys clinical studies, manufacturing operations, and production planning; (x) the Companys ability to successfully commercialize its products, in the U.S. and abroad; (xi) the Companys ability to provide an adequate and timely supply of its products to its customers; and (xii) the Companys ability to achieve its growth targets.Additional factors and risks are described in the Companys periodic reports filed with the Securities and Exchange Commission, and they are available on the SECs website at http://www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

Read this article:

Anika To Launch Six FDA-Cleared Sports Medicine and Extremities Products in Third Quarter of 2020 - OrthoSpineNews

UW Medicine and the Paul G. Allen Family Foundation Announce Study to Determine Prevalence of COVID-19 Infection Across Washington State – NBC Right…

SEATTLE, July 21, 2020 /PRNewswire/ --Today, the Washington State Department of Health, UW Medicine and the Paul G. Allen Family Foundation announced the launch of a major study to determine the percentage of Washingtonians who have been infected by COVID-19. UW Medicine's Virology Laboratory will conduct the study in close partnership with state and local public health agencies, sampling across rural and urban populations throughout the state and within racially, ethnically and socioeconomically diverse communities.

"Data is a crucial tool in helping us fight this pandemic and safely reopening our economy," Gov. Jay Inslee said. "This study and partnershipwillprovide vital insightsabout the trajectory of COVID-19 in Washington,informing our response and allowing usto betterprotect Washingtonians."

All 7,000 study participants will receive a diagnostic COVID-19 test followed by three antibody tests over the course of eight months. By including 7,000 participants, the study will provide statistically valid information about the distribution of COVID-19 in communities within our state. The results of the first antibody tests will indicate the baseline prevalence of infection to date. In addition to infection rates, the study will examine how long COVID-19 antibodies persist. This will inform the Department of Health's assessments and safety guidelines to control COVID-19 infections in communities across the state.

"As one of the first in the country to develop a COVID-19 test, UW Medicine has invested millions of dollars to build significant capacity for both COVID-19 and antibody testing at scale," said Dr. Keith Jerome, head of the Virology Division at UW Medicine. Jerome is the principal investigator of the study and directs multiple virology labs. Dr. Mark Wener, who directs the Immunology Division, will serve as the co-investigator and assist in the implementation.

The antibody tests will be processed at the UW Medicine Virology Lab, using the Abbott Architect SARS-CoV-2 IgG assay, which has been shown to have an extremely high degree of accuracy, to ensure that the resulting data is valid for use in statewide policy decisions. UW Medicine scientists were involved in evaluating the specificity of the test and are confident of its accuracy.

This study is funded by a $3.4 million grant from the Paul G. Allen Family Foundation and builds on the Foundation's previous support of UW Medicine's COVID-19 Emergency Response Fund, which has raised more than $30 million to date.

"Comprehensive, high-quality data that statistically represents Washington's diverse communities and populations is critical to support the state's healthcare response and reopening," said Jody Allen, co-founder and chair of the Paul G. Allen Family Foundation. "This statewide study will provide a necessary baseline understanding of COVID-19 presence in communities to inform smart policy decisions as we all move forward with Washington's economic and health recovery."

To learn more about this state-wide study, please visit UW Medicine Virology Lab.

Additional quotes from representatives of the Washington State Legislature

"This important study will help us better understand the prevalence of COVID-19 across Washington State, as well as make significant contributions to larger scientific questions that will benefit global efforts to address the pandemic," said Senator Mike Braun.

"I'm encouraged that this study will help provide additional context to understand the disparate impact of COVID-19 on populations outside of those that currently have greatest access to testing," said Senator Mark Mullet.

About UW Medicine

UW Medicine is one of the top-rated academic medical systems in the world. With a mission to improve the health of the public, UW Medicine educates the next generation of physicians and scientists, leads one of the world's largest and most comprehensive biomedical research programs, and provides outstanding care to patients from across the globe. The School of Medicine faculty is second in the nation in federal research grants and contracts with $923.1 million in total revenue (fiscal year 2018) according to the Association of American Medical Colleges.

About the Paul G. Allen Family Foundation

For more than four decades the Paul G. Allen Family Foundation has focused on changing the trajectory of some of the world's toughest problems. Founded by philanthropists Jody Allen and the late Paul G. Allen, co-founder of Microsoft, the Foundation initially invested in community needs across the Pacific Northwest with a focus on regional arts, under-served populations, and the environment. Today, the Foundation supports a global portfolio of frontline partners working to preserve ocean health, protect wildlife, combat climate change, and strengthen communities. The Foundation invests in grantees to leverage technology, fill data and science gaps, and drive positive public policy to advance knowledge and enable lasting change.

Media Contacts

UW Medicine: Susan Gregg, sghanson@uw.edu, (206) 616-6730

Paul G. Allen Family Foundation: press@pgafamilyfoundation.com, (206) 342-2230

See original here:

UW Medicine and the Paul G. Allen Family Foundation Announce Study to Determine Prevalence of COVID-19 Infection Across Washington State - NBC Right...

Single nanoparticle twists pave the way for medicines on demand: Study – Down To Earth Magazine

Understanding chirality twists within nanoparticles can help several industries, including pharma

The accurate measurement and characterisation of a single, twistednanoparticle in a laboratory for the first time has broughtthe pharmaceutical sector a step closer to produce and blend medicines on a microscopic scale.

The groundbreaking observations were made by physicists at the University of Bath, United Kingdom who measure molecules at the nanoscale, 10,000 times smaller than a pinhead.

The physicists studied the structure of gold and other materials, using a technique called the hyper-Rayleigh scattering optical activity, according to a July 20, 2020 press release from the university.

The technique allowed scientists to see a clear image of a screw thread twist in the gold nanoparticles shape.

Understanding the chirality twists within a material is critical for several industries, including the pharma sector, food additives, perfumes and pesticides.

This is because the direction in which a molecule twists determines some of its properties, said the press release, citing examples.

A molecule that twisted clockwise can produce the smell of lemons, while an anti-clockwise twist or a mirror-image of the lemon-smelling molecule produces the smell of oranges.

Chirality is one of the most fundamental properties of nature, said Ventsislav Valev, who headed the project and is a professor at Bath University.

It exists in sub-atomic particles, in molecules (DNA, proteins), in organs (the heart, the brain), in bio-materials (such as seashells), in storm clouds (tornadoes) and in the shape of galaxies (spirals hurling through space), he added.

There is immense potential for the practical applications of ultra-sensitive chiral sensing. Local pharmacists will now be able to mix substances in a new manner, using minute droplets of active ingredients instead of large beakers.

The ordinary consumer may, in the future, receive medicine in pills that are mini-labs rather than receiving them in bottles to be refrigerated, said Valev.

A precise number of micro-droplets will flow through micro-channels upon cracking the pill. This will mix and produce the needed medicine, explained Valev.

We can now aim to produce microdroplets containing a single chiral nanoparticle, to use as catalysts in chemical reactions, said PhD student Lukas Ohnoutek, the first author on the paper.

Chiral materials, including machines, can be built up one nanoparticle at a time from the microdroplets in the future, said Valev.

This is both a record and a milestone in nanotechnology, he added.

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.

Go here to read the rest:

Single nanoparticle twists pave the way for medicines on demand: Study - Down To Earth Magazine

OPINION EXCHANGE | Wall Street seems oblivious to the political threat of 2020 – Minneapolis Star Tribune

Coronavirus retreats. Stocks rally.

Coronavirus back on the rise. Stocks rally.

Jobs, sales rebound. Stocks rally.

Firms warn of fall layoffs, faltering sales. Stocks rally.

U.S.-China tensions ease. Stocks rally.

New U.S.-China cold war. Stocks rally.

In a momentum-driven stock market, it seems, all news is good news and any contrarian signs are rationalized away.

A rise in coronavirus deaths turns out to be good news for tech, telecom and drug companies and online retailers.

Warnings of disappointing sales and a fresh round of layoffs increase the probability of even more government stimulus.

The coming wave of defaults, bankruptcies and business closings turns into a golden opportunity for profit-enhancing mergers and acquisitions.

The latest threat to be discounted is the increasingly likely prospect that Democrats will sweep the 2020 elections, winning control of the White House and both houses of Congress. If that happens, the Senate filibuster will be history and Democrats will begin to exact their revenge on a business lobby that spent the past 25 years thwarting their legislative initiatives and financing the campaigns of their opponents.

Democrats may disagree about Medicare for All and the Green New Deal, but there are some things around which they will quickly coalesce:

Repealing every deregulatory initiative of the Trump administration while imposing new restrictions on coal companies and the oil and gas industry.

Repealing the Trump tax cuts and raising rates on business profits and profits made by individuals from the sale of stocks, bonds and real estate.

Repealing tax loopholes that benefit hedge fund and private equity managers and real estate developers.

Restricting stock buybacks.

Taxing financial transactions to discourage rapid-fire computerized trading and the hedge fund profits it generates.

Tripling the IRS budget for audits of corporate tax returns and crackdown on overseas tax shelters.

Launching aggressive antitrust cases to break up tech giants and telecom oligopolies.

Reforming the bankruptcy code to favor consumers and workers over banks and bottom-fishing hedge funds.

Raising the minimum wage and reforming labor laws to make it easier for workers to unionize.

Regulating, for the first time, the shadow banking system and derivatives market.

Imposing price caps on prescription drugs, medical devices and hospital services.

Overturning Supreme Court decisions limiting lawsuits against businesses by workers and consumers.

Requiring disclosure of corporate political spending laundered through secretive front groups and sham nonprofits.

To my way of thinking, many of these initiatives are long overdue and will in the long run enhance the performance of the American economy and restore the moral legitimacy of American capitalism. To the business lobby, they represent a nightmare scenario. But whatever your view, there can be little doubt that in the short and medium run the time horizon of most investors and corporate executives these policy changes will reduce the profits of businesses and the incomes of those who own them.

For that reason, its easy to imagine that stock prices already inflated by historical standards could fall by 25% with a Democratic sweep. Bond prices and real estate values would suffer smaller but still significant declines.

The question, then, is why does Wall Street remain oblivious to this political threat, just as it has been seemingly oblivious to a resurgent pandemic and the tidal wave of layoffs, bankruptcies and business failures that is about to break over the American economy?

The reason has partly to do with an excess of confidence in Congress and the Federal Reserve to borrow and print enough money to keep Americans employed and businesses from collapsing. A Democratic president with a Democratic Congress is even more likely than Republicans to open the fiscal tap to put an income floor under every household and stimulate public and private employment through government spending and investment. And as long as the rest of the world is willing to keep lending us money and accepting dollars in repayment, why should we stop?

The problem is that once the economy gets hooked on this open-ended borrowing, spending and money printing, it becomes harder and harder to dial it back without causing painful convulsions. Financial markets used to understand that. But after more than 10 years of extraordinary fiscal and monetary stimulus, there are too many people on Wall Street who know no other reality or have somehow convinced themselves that the basic laws of accounting and economics no longer apply.

Investors have also been lulled into complacency over the past three decades in which Americans came to embrace the idea that the only way to keep the economy competitive and growing was to put investor interests above those of everyone else. It is hardly a coincidence that as business norms and public policy adapted to the idea that businesses exist to maximize value for shareholders, the share of national income going to holders of capital investors rose by more than five percentage points. This trillion-dollar-a-year redistribution from workers to investors has become so normal that few in the business world even question it.

A clean sweep in November would almost certainly reverse that process, moving the country toward a different kind of capitalism with a different purpose and a different distribution of national income. That prospect, however, is so outside the experience of todays investors and business executives, and so at odds with their notion of how things are supposed to work, that they cannot imagine it let alone calculate how it might reduce value of their shares. So they are left to hope that a polarized politics, a weakened economy and some well-financed lobbying will stymie the Democratic agenda.

That may have once been possible, but no longer. Donald Trump, Mitch McConnell and the Freedom Caucus changed all that, as did the murder of George Floyd. Now the faux populism of the Republican Party is about to give way to the real populism of angry and vengeful Democrats. And by all appearances, the Wall Street wiseguys dont have a clue about whats coming their way.

Steven Pearlstein is a business and economics columnist. He was awarded the Pulitzer Prize for commentary in 2008 for columns anticipating and explaining the global financial crisis.

View original post here:

OPINION EXCHANGE | Wall Street seems oblivious to the political threat of 2020 - Minneapolis Star Tribune

The coronavirus crisis shows now is the time to demand more from our government – Wisconsin Examiner

.current-menu-item > a, .td-header-wrap .black-menu .sf-menu > .current-menu-ancestor > a, .td-header-wrap .black-menu .sf-menu > .current-category-ancestor > a, .td-header-wrap .black-menu .sf-menu > li > a:hover, .td-header-wrap .black-menu .sf-menu > .sfHover > a, .td-header-style-12 .td-header-menu-wrap-full, .sf-menu > .current-menu-item > a:after, .sf-menu > .current-menu-ancestor > a:after, .sf-menu > .current-category-ancestor > a:after, .sf-menu > li:hover > a:after, .sf-menu > .sfHover > a:after, .td-header-style-12 .td-affix, .header-search-wrap .td-drop-down-search:after, .header-search-wrap .td-drop-down-search .btn:hover, input[type=submit]:hover, .td-read-more a, .td-post-category:hover, .td-grid-style-1.td-hover-1 .td-big-grid-post:hover .td-post-category, .td-grid-style-5.td-hover-1 .td-big-grid-post:hover .td-post-category, .td_top_authors .td-active .td-author-post-count, .td_top_authors .td-active .td-author-comments-count, .td_top_authors .td_mod_wrap:hover .td-author-post-count, .td_top_authors .td_mod_wrap:hover .td-author-comments-count, .td-404-sub-sub-title a:hover, .td-search-form-widget .wpb_button:hover, .td-rating-bar-wrap div, .td_category_template_3 .td-current-sub-category, .dropcap, .td_wrapper_video_playlist .td_video_controls_playlist_wrapper, .wpb_default, .wpb_default:hover, .td-left-smart-list:hover, .td-right-smart-list:hover, .woocommerce-checkout .woocommerce input.button:hover, .woocommerce-page .woocommerce a.button:hover, .woocommerce-account div.woocommerce .button:hover, #bbpress-forums button:hover, .bbp_widget_login .button:hover, .td-footer-wrapper .td-post-category, .td-footer-wrapper .widget_product_search input[type="submit"]:hover, .woocommerce .product a.button:hover, .woocommerce .product #respond input#submit:hover, .woocommerce .checkout input#place_order:hover, .woocommerce .woocommerce.widget .button:hover, .single-product .product .summary .cart .button:hover, .woocommerce-cart .woocommerce table.cart .button:hover, .woocommerce-cart .woocommerce .shipping-calculator-form .button:hover, .td-next-prev-wrap a:hover, .td-load-more-wrap a:hover, .td-post-small-box a:hover, .page-nav .current, .page-nav:first-child > div, .td_category_template_8 .td-category-header .td-category a.td-current-sub-category, .td_category_template_4 .td-category-siblings .td-category a:hover, #bbpress-forums .bbp-pagination .current, #bbpress-forums #bbp-single-user-details #bbp-user-navigation li.current a, .td-theme-slider:hover .slide-meta-cat a, a.vc_btn-black:hover, .td-trending-now-wrapper:hover .td-trending-now-title, .td-scroll-up, .td-smart-list-button:hover, .td-weather-information:before, .td-weather-week:before, .td_block_exchange .td-exchange-header:before, .td_block_big_grid_9.td-grid-style-1 .td-post-category, .td_block_big_grid_9.td-grid-style-5 .td-post-category, .td-grid-style-6.td-hover-1 .td-module-thumb:after, .td-pulldown-syle-2 .td-subcat-dropdown ul:after, .td_block_template_9 .td-block-title:after, .td_block_template_15 .td-block-title:before, div.wpforms-container .wpforms-form div.wpforms-submit-container button[type=submit] { background-color: #1e73be; } .td_block_template_4 .td-related-title .td-cur-simple-item:before { border-color: #1e73be transparent transparent transparent !important; } .woocommerce .woocommerce-message .button:hover, .woocommerce .woocommerce-error .button:hover, .woocommerce .woocommerce-info .button:hover { background-color: #1e73be !important; } .td_block_template_4 .td-related-title .td-cur-simple-item, .td_block_template_3 .td-related-title .td-cur-simple-item, .td_block_template_9 .td-related-title:after { background-color: #1e73be; } .woocommerce .product .onsale, .woocommerce.widget .ui-slider .ui-slider-handle { background: none #1e73be; } .woocommerce.widget.widget_layered_nav_filters ul li a { background: none repeat scroll 0 0 #1e73be !important; } a, cite a:hover, .td_mega_menu_sub_cats .cur-sub-cat, .td-mega-span h3 a:hover, .td_mod_mega_menu:hover .entry-title a, .header-search-wrap .result-msg a:hover, .td-header-top-menu .td-drop-down-search .td_module_wrap:hover .entry-title a, .td-header-top-menu .td-icon-search:hover, .td-header-wrap .result-msg a:hover, .top-header-menu li a:hover, .top-header-menu .current-menu-item > a, .top-header-menu .current-menu-ancestor > a, .top-header-menu .current-category-ancestor > a, .td-social-icon-wrap > a:hover, .td-header-sp-top-widget .td-social-icon-wrap a:hover, .td-page-content blockquote p, .td-post-content blockquote p, .mce-content-body blockquote p, .comment-content blockquote p, .wpb_text_column blockquote p, .td_block_text_with_title blockquote p, .td_module_wrap:hover .entry-title a, .td-subcat-filter .td-subcat-list a:hover, .td-subcat-filter .td-subcat-dropdown a:hover, .td_quote_on_blocks, .dropcap2, .dropcap3, .td_top_authors .td-active .td-authors-name a, .td_top_authors .td_mod_wrap:hover .td-authors-name a, .td-post-next-prev-content a:hover, .author-box-wrap .td-author-social a:hover, .td-author-name a:hover, .td-author-url a:hover, .td_mod_related_posts:hover h3 > a, .td-post-template-11 .td-related-title .td-related-left:hover, .td-post-template-11 .td-related-title .td-related-right:hover, .td-post-template-11 .td-related-title .td-cur-simple-item, .td-post-template-11 .td_block_related_posts .td-next-prev-wrap a:hover, .comment-reply-link:hover, .logged-in-as a:hover, #cancel-comment-reply-link:hover, .td-search-query, .td-category-header .td-pulldown-category-filter-link:hover, .td-category-siblings .td-subcat-dropdown a:hover, .td-category-siblings .td-subcat-dropdown a.td-current-sub-category, .widget a:hover, .td_wp_recentcomments a:hover, .archive .widget_archive .current, .archive .widget_archive .current a, .widget_calendar tfoot a:hover, .woocommerce a.added_to_cart:hover, .woocommerce-account .woocommerce-MyAccount-navigation a:hover, #bbpress-forums li.bbp-header .bbp-reply-content span a:hover, #bbpress-forums .bbp-forum-freshness a:hover, #bbpress-forums .bbp-topic-freshness a:hover, #bbpress-forums .bbp-forums-list li a:hover, #bbpress-forums .bbp-forum-title:hover, #bbpress-forums .bbp-topic-permalink:hover, #bbpress-forums .bbp-topic-started-by a:hover, #bbpress-forums .bbp-topic-started-in a:hover, #bbpress-forums .bbp-body .super-sticky li.bbp-topic-title .bbp-topic-permalink, #bbpress-forums .bbp-body .sticky li.bbp-topic-title .bbp-topic-permalink, .widget_display_replies .bbp-author-name, .widget_display_topics .bbp-author-name, .footer-text-wrap .footer-email-wrap a, .td-subfooter-menu li a:hover, .footer-social-wrap a:hover, a.vc_btn-black:hover, .td-smart-list-dropdown-wrap .td-smart-list-button:hover, .td_module_17 .td-read-more a:hover, .td_module_18 .td-read-more a:hover, .td_module_19 .td-post-author-name a:hover, .td-instagram-user a, .td-pulldown-syle-2 .td-subcat-dropdown:hover .td-subcat-more span, .td-pulldown-syle-2 .td-subcat-dropdown:hover .td-subcat-more i, .td-pulldown-syle-3 .td-subcat-dropdown:hover .td-subcat-more span, .td-pulldown-syle-3 .td-subcat-dropdown:hover .td-subcat-more i, .td-block-title-wrap .td-wrapper-pulldown-filter .td-pulldown-filter-display-option:hover, .td-block-title-wrap .td-wrapper-pulldown-filter .td-pulldown-filter-display-option:hover i, .td-block-title-wrap .td-wrapper-pulldown-filter .td-pulldown-filter-link:hover, .td-block-title-wrap .td-wrapper-pulldown-filter .td-pulldown-filter-item .td-cur-simple-item, .td_block_template_2 .td-related-title .td-cur-simple-item, .td_block_template_5 .td-related-title .td-cur-simple-item, .td_block_template_6 .td-related-title .td-cur-simple-item, .td_block_template_7 .td-related-title .td-cur-simple-item, .td_block_template_8 .td-related-title .td-cur-simple-item, .td_block_template_9 .td-related-title .td-cur-simple-item, .td_block_template_10 .td-related-title .td-cur-simple-item, .td_block_template_11 .td-related-title .td-cur-simple-item, .td_block_template_12 .td-related-title .td-cur-simple-item, .td_block_template_13 .td-related-title .td-cur-simple-item, .td_block_template_14 .td-related-title .td-cur-simple-item, .td_block_template_15 .td-related-title .td-cur-simple-item, .td_block_template_16 .td-related-title .td-cur-simple-item, .td_block_template_17 .td-related-title .td-cur-simple-item, .td-theme-wrap .sf-menu ul .td-menu-item > a:hover, .td-theme-wrap .sf-menu ul .sfHover > a, .td-theme-wrap .sf-menu ul .current-menu-ancestor > a, .td-theme-wrap .sf-menu ul .current-category-ancestor > a, .td-theme-wrap .sf-menu ul .current-menu-item > a, .td_outlined_btn { color: #1e73be; } a.vc_btn-black.vc_btn_square_outlined:hover, a.vc_btn-black.vc_btn_outlined:hover, .td-mega-menu-page .wpb_content_element ul li a:hover, .td-theme-wrap .td-aj-search-results .td_module_wrap:hover .entry-title a, .td-theme-wrap .header-search-wrap .result-msg a:hover { color: #1e73be !important; } .td-next-prev-wrap a:hover, .td-load-more-wrap a:hover, .td-post-small-box a:hover, .page-nav .current, .page-nav:first-child > div, .td_category_template_8 .td-category-header .td-category a.td-current-sub-category, .td_category_template_4 .td-category-siblings .td-category a:hover, #bbpress-forums .bbp-pagination .current, .post .td_quote_box, .page .td_quote_box, a.vc_btn-black:hover, .td_block_template_5 .td-block-title > *, .td_outlined_btn { border-color: #1e73be; } .td_wrapper_video_playlist .td_video_currently_playing:after { border-color: #1e73be !important; } .header-search-wrap .td-drop-down-search:before { border-color: transparent transparent #1e73be transparent; } .block-title > span, .block-title > a, .block-title > label, .widgettitle, .widgettitle:after, .td-trending-now-title, .td-trending-now-wrapper:hover .td-trending-now-title, .wpb_tabs li.ui-tabs-active a, .wpb_tabs li:hover a, .vc_tta-container .vc_tta-color-grey.vc_tta-tabs-position-top.vc_tta-style-classic .vc_tta-tabs-container .vc_tta-tab.vc_active > a, .vc_tta-container .vc_tta-color-grey.vc_tta-tabs-position-top.vc_tta-style-classic .vc_tta-tabs-container .vc_tta-tab:hover > a, .td_block_template_1 .td-related-title .td-cur-simple-item, .woocommerce .product .products h2:not(.woocommerce-loop-product__title), .td-subcat-filter .td-subcat-dropdown:hover .td-subcat-more, .td_3D_btn, .td_shadow_btn, .td_default_btn, .td_round_btn, .td_outlined_btn:hover { background-color: #1e73be; } .woocommerce div.product .woocommerce-tabs ul.tabs li.active { background-color: #1e73be !important; } .block-title, .td_block_template_1 .td-related-title, .wpb_tabs .wpb_tabs_nav, .vc_tta-container .vc_tta-color-grey.vc_tta-tabs-position-top.vc_tta-style-classic .vc_tta-tabs-container, .woocommerce div.product .woocommerce-tabs ul.tabs:before { border-color: #1e73be; } .td_block_wrap .td-subcat-item a.td-cur-simple-item { color: #1e73be;} .td-grid-style-4 .entry-title { background-color: rgba(30, 115, 190, 0.7); } .td-header-wrap .td-header-menu-social .td-social-icon-wrap a { color: #dd9933; }]]> .current-menu-item > a, .td-header-wrap .black-menu .sf-menu > .current-menu-ancestor > a, .td-header-wrap .black-menu .sf-menu > .current-category-ancestor > a, .td-header-wrap .black-menu .sf-menu > li > a:hover, .td-header-wrap .black-menu .sf-menu > .sfHover > a, .td-header-style-12 .td-header-menu-wrap-full, .sf-menu > .current-menu-item > a:after, .sf-menu > .current-menu-ancestor > a:after, .sf-menu > .current-category-ancestor > a:after, .sf-menu > li:hover > a:after, .sf-menu > .sfHover > a:after, .td-header-style-12 .td-affix, .header-search-wrap .td-drop-down-search:after, .header-search-wrap .td-drop-down-search .btn:hover, input[type=submit]:hover, .td-read-more a, .td-post-category:hover, .td-grid-style-1.td-hover-1 .td-big-grid-post:hover .td-post-category, .td-grid-style-5.td-hover-1 .td-big-grid-post:hover .td-post-category, .td_top_authors .td-active .td-author-post-count, .td_top_authors .td-active .td-author-comments-count, .td_top_authors .td_mod_wrap:hover .td-author-post-count, .td_top_authors .td_mod_wrap:hover .td-author-comments-count, .td-404-sub-sub-title a:hover, .td-search-form-widget .wpb_button:hover, .td-rating-bar-wrap div, .td_category_template_3 .td-current-sub-category, .dropcap, .td_wrapper_video_playlist .td_video_controls_playlist_wrapper, .wpb_default, .wpb_default:hover, .td-left-smart-list:hover, .td-right-smart-list:hover, .woocommerce-checkout .woocommerce input.button:hover, .woocommerce-page .woocommerce a.button:hover, .woocommerce-account div.woocommerce .button:hover, #bbpress-forums button:hover, .bbp_widget_login .button:hover, .td-footer-wrapper .td-post-category, .td-footer-wrapper .widget_product_search input[type="submit"]:hover, .woocommerce .product a.button:hover, .woocommerce .product #respond input#submit:hover, .woocommerce .checkout input#place_order:hover, .woocommerce .woocommerce.widget .button:hover, .single-product .product .summary .cart .button:hover, .woocommerce-cart .woocommerce table.cart .button:hover, .woocommerce-cart .woocommerce .shipping-calculator-form .button:hover, .td-next-prev-wrap a:hover, .td-load-more-wrap a:hover, .td-post-small-box a:hover, .page-nav .current, .page-nav:first-child > div, .td_category_template_8 .td-category-header .td-category a.td-current-sub-category, .td_category_template_4 .td-category-siblings .td-category a:hover, #bbpress-forums .bbp-pagination .current, #bbpress-forums #bbp-single-user-details #bbp-user-navigation li.current a, .td-theme-slider:hover .slide-meta-cat a, a.vc_btn-black:hover, .td-trending-now-wrapper:hover .td-trending-now-title, .td-scroll-up, .td-smart-list-button:hover, .td-weather-information:before, .td-weather-week:before, .td_block_exchange .td-exchange-header:before, .td_block_big_grid_9.td-grid-style-1 .td-post-category, .td_block_big_grid_9.td-grid-style-5 .td-post-category, .td-grid-style-6.td-hover-1 .td-module-thumb:after, .td-pulldown-syle-2 .td-subcat-dropdown ul:after, .td_block_template_9 .td-block-title:after, .td_block_template_15 .td-block-title:before, div.wpforms-container .wpforms-form div.wpforms-submit-container button[type=submit] { background-color: #749FD4 !important; }.subContainer a {flex-direction: inherit; display: flex; width: 100%;}]]> .current-category-ancestor > a, .tdm-menu-active-style3 .tdm-header.td-header-wrap .sf-menu > .current-menu-ancestor > a, .tdm-menu-active-style3 .tdm-header.td-header-wrap .sf-menu > .current-menu-item > a, .tdm-menu-active-style3 .tdm-header.td-header-wrap .sf-menu > .sfHover > a, .tdm-menu-active-style3 .tdm-header.td-header-wrap .sf-menu > li > a:hover, .tdm_block_column_content:hover .tdm-col-content-title-url .tdm-title, .tds-button2 .tdm-btn-text, .tds-button2 i, .tds-button5:hover .tdm-btn-text, .tds-button5:hover i, .tds-button6 .tdm-btn-text, .tds-button6 i, .tdm_block_list .tdm-list-item i, .tdm_block_pricing .tdm-pricing-feature i, .tdm-social-item i { color: #1e73be; } .tdm-menu-active-style5 .td-header-menu-wrap .sf-menu > .current-menu-item > a, .tdm-menu-active-style5 .td-header-menu-wrap .sf-menu > .current-menu-ancestor > a, .tdm-menu-active-style5 .td-header-menu-wrap .sf-menu > .current-category-ancestor > a, .tdm-menu-active-style5 .td-header-menu-wrap .sf-menu > li > a:hover, .tdm-menu-active-style5 .td-header-menu-wrap .sf-menu > .sfHover > a, .tds-button1, .tds-button6:after, .tds-title2 .tdm-title-line:after, .tds-title3 .tdm-title-line:after, .tdm_block_pricing.tdm-pricing-featured:before, .tdm_block_pricing.tds_pricing2_block.tdm-pricing-featured .tdm-pricing-header, .tds-progress-bar1 .tdm-progress-bar:after, .tds-progress-bar2 .tdm-progress-bar:after, .tds-social3 .tdm-social-item { background-color: #1e73be; } .tdm-menu-active-style4 .tdm-header .sf-menu > .current-menu-item > a, .tdm-menu-active-style4 .tdm-header .sf-menu > .current-menu-ancestor > a, .tdm-menu-active-style4 .tdm-header .sf-menu > .current-category-ancestor > a, .tdm-menu-active-style4 .tdm-header .sf-menu > li > a:hover, .tdm-menu-active-style4 .tdm-header .sf-menu > .sfHover > a, .tds-button2:before, .tds-button6:before, .tds-progress-bar3 .tdm-progress-bar:after { border-color: #1e73be; } .tdm-btn-style1 {background-color: #1e73be;}.tdm-btn-style2:before { border-color: #1e73be;}.tdm-btn-style2 { color: #1e73be;}.tdm-btn-style3 { -webkit-box-shadow: 0 2px 16px #1e73be; -moz-box-shadow: 0 2px 16px #1e73be; box-shadow: 0 2px 16px #1e73be;}.tdm-btn-style3:hover { -webkit-box-shadow: 0 4px 26px #1e73be; -moz-box-shadow: 0 4px 26px #1e73be; box-shadow: 0 4px 26px #1e73be;}]]>

America hasblown pastevery country in the coronavirus pandemic, with almost 4 million cases and more than 140,000 deaths.

If you want to know why the most medically advanced country in the world ended up here, look no further than the malfeasance and conspiracy-mongering of President Donald Trump. TheNew York Timesthis weekend ran a devastating tick-tock of the White Houses disastrous response, fed by Trumps sycophants, like making governors beg and compete against each other for vital medical equipment (like a sick Hunger Games, as Illinois Gov. J.B. Pritzker put it) and failing to issue national lockdown (and later) mask orders while encouragingarmed insurrections against governors who did, like Gov. Gretchen Whitmer and Gov. Tony Evers with his Safer at Home order.

Its now culminated in Trumps order to slow down testing (he told us hewasnt kidding) and the immoral strategy of justignoringmass death thats now rockingstates,even those he needs to win in November.

Weve also completely blown our obligation to make sure people survive the pain of COVID-19 in every form. Look around the world at other democracies with competent leadership. Countries from Germany to New Zealand to South Korea are reopening landmarks and schools, while people are enjoying restaurants and traveling.

Meanwhile, in America, were fighting with angry Kyles and Karens over donning masks in Walmart so they dont infect everyone as they fly into a spit-flinging rage while demanding to speak to the manager.

Weve barely prepared for in-person learning, with Trump and Education Secretary Betsy DeVos putting a fiscal gun to the head of states that dont follow their poorly drawnplans(which they really cant make good on). And a U.S.passportis basically worthless, as few nations will let Americans in thanks to our failure to get COVID-19 under control.

But our biggest failure is in our moral obligation to take care of the 328 million people who live in our country during perhaps the most harrowing time in modern history. Its true that legislation like the Paycheck Protection Plan helped keep some businesses afloat, even as funds lined the pockets of questionable entities, includingTrump allies, theCatholic Churchandyacht clubsin Michigan.

And theCARES Actwas one of the more generous safety net packages weve had in recent decades, helping millions stay afloat by beefing up unemployment benefits, a $1,200 lump sum payment for most people and aid to states and hospitals to respond to coronavirus. But jobless benefits run out this month and many states, including Michigan, are still reeling from the recession.

Congress also failed to require sick time for most employees, which especially hurt essential workers in warehouses and grocery stories, thanks to intense lobbying from theU.S. Chamber of Commerceand corporations. The Trump administration refused to do an open enrollment in Obamacare for the millions who lost their employer-provided insurance.

And after endlessmedia storiesabout how the $600 weekly unemployment benefit was just too darn generous because it actually allowed people to survive and, in some cases, gave them the freedom not to go back to unsafe working conditions, the GOP-led U.S. Senate is determined to ax or drastically shrink the amount. Forcing people back into the workplace has the added bonus of juicing the economy (and, they hope, Trumps reelection chances), even if it literally kills people as the pandemic is spinning out of control.

Thats the kind of collateral damage Trump and most Republicans are quite willing to live with.

The fact that this inhumane GOP response is barely questioned and that the supposedly liberal media is quite comfortable playing the role of fiscal scold to millions of low-income Americans, disproportionately people of color, who literally just want to stay alive and pay their bills, underscores why America has failed so spectacularly in this moment.

There is no reason why so many people had to get sick, financially suffer and die at this time. This did not happen in other democratic countries. The pandemic has been a perfect storm, revealing in stark relief the inequities in our health care system and how tattered our safety net is.

Now is the time to blow things up. Everyone deserves good health care, childcare, sick leave, housing, education and assistance when they are down and out. Theres nothing radical about this in an era when we have the skills and know-how to likely develop a COVID-19 vaccine by next year.

What good is human suffering when we have the ability to eliminate much of it? This is a promise we owe each other and yes, the government should pay for it.

It wont be easy. Universal health care which again, every rich nation has, although not necessarily single-payer will cause massive disruption in a system that has creaked along for decades. But health care has already been upended by a pandemic, so if there was ever a time, its now. Theres a reason why many European countries adopted their plans after World War II, after all.

And we are the richest country in the world. Nobody bats an eye at the crippling cost of the military or the taxpayer dollars Trump spends padding his own businesses, keeping migrant kids in cages anddeployingfederal agents to blue cities to crack down on Black Lives Matter protesters.

None of this will be politically easy. Realistically, even if we elected a Democratic president and Congress this fall, more moderate members will be wary. Trump has also stacked the courts with radical right-wing judges salivating over the chance to kill every progressive dream alive.

THE MORNING NEWSLETTER

Subscribe now.

Knowing the history of this country with social change, Democrats affinity for compromise, even when Republicans laugh in their faces, and the total opposition of the super-rich and corporations, I know the odds are against us.

But I also know that if we dont start demanding more now, we never will. Poor people, working-class people, women and people of color must seize this terrible moment and make the case for something better, for a renewed America truly rooted in fairness, justice and equality.

It is, quite simply, what we owe ourselves and each other.

Susan J. Demas is an 18-year journalism veteran and one of the states foremost experts on Michigan politics, appearing on MSNBC, CNN, NPR and WKAR-TVs Off the Record. In addition to serving as Editor-in-Chief, she is the Advances chief columnist, writing on women, LGBTQs, the state budget, the economy and more. Most recently, she served as Vice President of Farough & Associates, Michigans premier political communications firm. For almost five years, Susan was the Editor and Publisher of Inside Michigan Politics, the most-cited political newsletter in the state. Susans award-winning political analysis has run in more than 80 national, international and regional media outlets, including the Guardian U.K., NBC News, the New York Times, the Detroit News and MLive. She is the only Michigan journalist to be named to the Washington Posts list of Best Political Reporters, the Huffington Posts list of Best Political Tweeters and the Washington Posts list of Best Political Bloggers. Susan was the recipient of a prestigious Knight Foundation fellowship in nonprofits and politics. She served as Deputy Editor for MIRS News and helped launch the Michigan Truth Squad, the Center for Michigans fact-checking project. She started her journalism career reporting on the Iowa caucuses for The (Cedar Rapids) Gazette.

Adjust Font Size

A-A+Reset Font Size

Spotlight Tab Key Navigation

Go here to see the original:

The coronavirus crisis shows now is the time to demand more from our government - Wisconsin Examiner

DIMOND: The Hypocrisy of the Black Lives Matter Movement – Rockland County Times

BY DIANE DIMOND

Black lives matter. Of course they do. But it is now abundantly clear that the lives, safety and dignity of Black men, women and children are not really what drives organizers of the Black Lives Matter movement. That is a shame.

The world has been fed a bill of goods about BLMs goals. Now we see they are about creating civil unrest and nothing more. We should have realized this after one of its co-founders proudly declared she is a trained Marxist. Marxism, by definition, argues for a worker revolution to overturn capitalism in favor of communism.

The BLM website says the group builds power to bring justice, healing, and freedom to black people. Really? Then why havent they mobilized in hotspot neighborhoods where blacks are most frequently victimized?

In New York, BLM organizers concentrate on painting their name on streets yet do nothing to help stop the ever-increasing civilian slaughter of mostly black citizens. Shootings during the first six months of this year are up 46 percent, and homicides increased more than 20 percent. Yet BLMs cries for defunding the police continue, and the mayors response was to cut $1 billion from the NYPD budget. The departments anti-crime unit focused on disarming criminals and curbing violent crime in mostly minority neighborhoods was disbanded.

In what world does that make sense?

The latest shock to New Yorkers came when a 22-month-old baby boy, Davell Gardner, was senselessly shot and killed at a Brooklyn barbecue. The shooting also left three adult men wounded. All the victims were black, and police suspect the shooters were, too.

They (are) talking about Black Lives Matter,' said Davells grieving grandmother, but black lives dont matter because Black people (are) trying to kill other Black people. Samantha Garner added what we are all thinking: It needs to stop! Catch the bastards!

In Chicago, where more than 100 mostly Black people were shot by civilians over a recent weekend, one local reverend said its an open season killing field. Nearly 2,000 Chicagoans have been shot so far this year, hundreds fatally, and, yes, the majority of victims and known assailants are black

So, where is the Black Lives Matter movement in Chicago to try to curb this trend? Has BLM piled into the Windy City to marshal local ministers, community leaders and concerned citizens to try to combat the carnage against black Americans? No.

In Minneapolis, authorities report at least 116 people were shot in the four weeks following the death of George Floyd. Recently, there were three gang-related shootings in one day, one in a majority-Black neighborhood in north Minneapolis where 50 children (ages 5 to 14) were at football practice. One eyewitness, a mother, posted a chilling video saying the shooters obviously had no regard for life. Luckily, no child was shot.

Did Black Lives Matter come in to help soothe the psychic wounds of those mostly Black children or to mobilize grown-ups to guard against another incident? No.

In Atlanta, at the burned-out Wendys restaurant where BLM gathered after police killed a Black man who shot at them with a Taser, another tragedy took place. An 8-year-old black child was fatally shot as she rode by in a car. It was yet another mindless black-on-black shooting. Her father later told the criminals: You killed a child. She didnt do nothing to nobody. Black Lives Matter? You killing your own.

The mantra of Black Lives Matter is now part of the American lexicon. All clear-thinking citizens embrace it and the idea that violent police tactics need to be abolished. Embracing those ideals and the BLM organization are two very different things.

The movement funded with multiple millions of dollars donated by well-meaning corporations, celebrities and concerned people is fatally flawed. BLM lacks true leadership, fiscal transparency and an explicit mission statement. To be viable, the organization must condemn the violence perpetrated in its name, along with the illegal occupations, the burning and looting, and the vandalism so frequently seen. So far, we havent heard a peep from their self-described Marxist leadership.

Remembering the lessons from the righteous civil rights era of the 50s and 60s, I often wonder what Dr. Martin Luther King Jr. or Rosa Parks would think about todays movement for racial justice. I believe they would be greatly disappointed.

Rockland County resident Diane Dimond is a journalist, author, and a regular contributing correspondent for the Investigation Discovery channel. To find out more about Dimond, visit her website at http://www.dianedimond.com

Original post:

DIMOND: The Hypocrisy of the Black Lives Matter Movement - Rockland County Times